Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis
Background: Osteoporosis is a significant concern, especially for individuals undergoing renal transplantation, as it disrupts bone health and increases the risk of fractures. Interventions for osteoporosis aim to address bone-related challenges in patients with renal transplantation, yet concerns p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shahid Beheshti University of Medical Sciences
2024-09-01
|
| Series: | Novelty in Biomedicine |
| Subjects: | |
| Online Access: | https://journals.sbmu.ac.ir/nbm/article/view/44677 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594053857804288 |
|---|---|
| author | Amir Sheikholeslami Amir Behnam Kharazmi Tahereh Sabaghian Mohammad Javad Nasiri |
| author_facet | Amir Sheikholeslami Amir Behnam Kharazmi Tahereh Sabaghian Mohammad Javad Nasiri |
| author_sort | Amir Sheikholeslami |
| collection | DOAJ |
| description | Background: Osteoporosis is a significant concern, especially for individuals undergoing renal transplantation, as it disrupts bone health and increases the risk of fractures. Interventions for osteoporosis aim to address bone-related challenges in patients with renal transplantation, yet concerns persist regarding both efficacy and potential adverse events.
Materials and Methods: We searched PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL databases until December 15, 2023, seeking studies that evaluated the efficacy and adverse events of osteoporosis medications in patients with renal transplantation. The Cochrane tool was utilized to assess the quality of the studies. The statistical analysis was performed using Comprehensive Meta-Analysis software, version 3.0.
Results: We enrolled 594 participants from 7 randomized controlled trials. Combining trial results reveals that using anti-osteoporotic agents (Ibandronate, Risedronate, and Pamidronate) reduces the risk of vertebral fractures compared to the placebo. However, the reduction was not statistically significant (OR: 0.49, CI 95%: 0.20-1.22). Additionally, lumbar spine, femoral neck, and total hip BMD showed no significant differences between anti-osteoporotic agents (Denosumab, Zoledronic acid, Ibandronate, Risedronate, and Pamidronate) and placebo. Moreover, there were no significant differences in adverse events between the interventions and placebo.
Conclusion: The study suggests that anti-osteoporotic agents in renal transplantation patients may be associated with a non-significant lower risk of vertebral fractures compared to a placebo. Findings also indicate no significant differences in adverse events between interventions and placebos. Caution is advised in interpreting these results due to the absence of statistically significant differences, emphasizing the need for further research to enhance our understanding of efficacy and safety in renal transplantation. |
| format | Article |
| id | doaj-art-1a8b480fe3c745329903f05ba27e9a15 |
| institution | Kabale University |
| issn | 2345-3907 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Shahid Beheshti University of Medical Sciences |
| record_format | Article |
| series | Novelty in Biomedicine |
| spelling | doaj-art-1a8b480fe3c745329903f05ba27e9a152025-01-20T05:02:55ZengShahid Beheshti University of Medical SciencesNovelty in Biomedicine2345-39072024-09-0112410.22037/nbm.v12i4.4467734564Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-AnalysisAmir Sheikholeslami0Amir Behnam Kharazmi1Tahereh Sabaghian2Mohammad Javad Nasiri3 1Department of Medical Oncology, Hematology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran2Department of Internal Medicine, Imam Hossein Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.3Clinical Research Development Center, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.4School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranBackground: Osteoporosis is a significant concern, especially for individuals undergoing renal transplantation, as it disrupts bone health and increases the risk of fractures. Interventions for osteoporosis aim to address bone-related challenges in patients with renal transplantation, yet concerns persist regarding both efficacy and potential adverse events. Materials and Methods: We searched PubMed/MEDLINE, EMBASE, and the Cochrane CENTRAL databases until December 15, 2023, seeking studies that evaluated the efficacy and adverse events of osteoporosis medications in patients with renal transplantation. The Cochrane tool was utilized to assess the quality of the studies. The statistical analysis was performed using Comprehensive Meta-Analysis software, version 3.0. Results: We enrolled 594 participants from 7 randomized controlled trials. Combining trial results reveals that using anti-osteoporotic agents (Ibandronate, Risedronate, and Pamidronate) reduces the risk of vertebral fractures compared to the placebo. However, the reduction was not statistically significant (OR: 0.49, CI 95%: 0.20-1.22). Additionally, lumbar spine, femoral neck, and total hip BMD showed no significant differences between anti-osteoporotic agents (Denosumab, Zoledronic acid, Ibandronate, Risedronate, and Pamidronate) and placebo. Moreover, there were no significant differences in adverse events between the interventions and placebo. Conclusion: The study suggests that anti-osteoporotic agents in renal transplantation patients may be associated with a non-significant lower risk of vertebral fractures compared to a placebo. Findings also indicate no significant differences in adverse events between interventions and placebos. Caution is advised in interpreting these results due to the absence of statistically significant differences, emphasizing the need for further research to enhance our understanding of efficacy and safety in renal transplantation.https://journals.sbmu.ac.ir/nbm/article/view/44677osteoporosisrenal transplantationadverse eventsefficacy |
| spellingShingle | Amir Sheikholeslami Amir Behnam Kharazmi Tahereh Sabaghian Mohammad Javad Nasiri Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis Novelty in Biomedicine osteoporosis renal transplantation adverse events efficacy |
| title | Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis |
| title_full | Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis |
| title_fullStr | Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis |
| title_short | Efficacy and Safety of Osteoporosis Medication in Renal Transplantation: A Systematic Review and Meta-Analysis |
| title_sort | efficacy and safety of osteoporosis medication in renal transplantation a systematic review and meta analysis |
| topic | osteoporosis renal transplantation adverse events efficacy |
| url | https://journals.sbmu.ac.ir/nbm/article/view/44677 |
| work_keys_str_mv | AT amirsheikholeslami efficacyandsafetyofosteoporosismedicationinrenaltransplantationasystematicreviewandmetaanalysis AT amirbehnamkharazmi efficacyandsafetyofosteoporosismedicationinrenaltransplantationasystematicreviewandmetaanalysis AT taherehsabaghian efficacyandsafetyofosteoporosismedicationinrenaltransplantationasystematicreviewandmetaanalysis AT mohammadjavadnasiri efficacyandsafetyofosteoporosismedicationinrenaltransplantationasystematicreviewandmetaanalysis |